tsh biopharmoration Ltd
TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others. It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid … Read more
tsh biopharmoration Ltd (8432) - Net Assets
Latest net assets as of June 2025: NT$1.58 Billion TWD
Based on the latest financial reports, tsh biopharmoration Ltd (8432) has net assets worth NT$1.58 Billion TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.85 Billion) and total liabilities (NT$273.54 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.58 Billion |
| % of Total Assets | 85.23% |
| Annual Growth Rate | 5.09% |
| 5-Year Change | 44.09% |
| 10-Year Change | N/A |
| Growth Volatility | 10.41 |
tsh biopharmoration Ltd - Net Assets Trend (2017–2024)
This chart illustrates how tsh biopharmoration Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for tsh biopharmoration Ltd (2017–2024)
The table below shows the annual net assets of tsh biopharmoration Ltd from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.62 Billion | +28.17% |
| 2023-12-31 | NT$1.27 Billion | +4.42% |
| 2022-12-31 | NT$1.21 Billion | +11.91% |
| 2021-12-31 | NT$1.08 Billion | -3.79% |
| 2020-12-31 | NT$1.13 Billion | +0.12% |
| 2019-12-31 | NT$1.12 Billion | +0.36% |
| 2018-12-31 | NT$1.12 Billion | -2.24% |
| 2017-12-31 | NT$1.15 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to tsh biopharmoration Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 103.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$354.61 Million | 25.48% |
| Other Components | NT$1.04 Billion | 74.52% |
| Total Equity | NT$1.39 Billion | 100.00% |
tsh biopharmoration Ltd Competitors by Market Cap
The table below lists competitors of tsh biopharmoration Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BE Group AB (publ)
F:BGA1
|
$23.57 Million |
|
MHC Plantations Bhd
KLSE:5026
|
$23.58 Million |
|
Atrem S.A.
WAR:ATR
|
$23.59 Million |
|
Pureun Mutual Savings Bank Co. Ltd
KQ:007330
|
$23.59 Million |
|
Glintt
LS:GLINT
|
$23.54 Million |
|
S.D. STANDARD ETC DL-03
F:S1P
|
$23.54 Million |
|
Optrontec Inc
KQ:082210
|
$23.54 Million |
|
Thunder Bridge Capital Partners IV Inc
NASDAQ:THCP
|
$23.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in tsh biopharmoration Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,107,600,000 to 1,391,792,000, a change of 284,192,000 (25.7%).
- Net income of 113,093,000 contributed positively to equity growth.
- Dividend payments of 49,150,000 reduced retained earnings.
- Other factors increased equity by 220,249,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$113.09 Million | +8.13% |
| Dividends Paid | NT$49.15 Million | -3.53% |
| Other Changes | NT$220.25 Million | +15.82% |
| Total Change | NT$- | 25.66% |
Book Value vs Market Value Analysis
This analysis compares tsh biopharmoration Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.42x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.72x to 1.42x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$29.86 | NT$51.50 | x |
| 2018-12-31 | NT$29.19 | NT$51.50 | x |
| 2019-12-31 | NT$29.30 | NT$51.50 | x |
| 2020-12-31 | NT$29.31 | NT$51.50 | x |
| 2021-12-31 | NT$28.29 | NT$51.50 | x |
| 2022-12-31 | NT$29.54 | NT$51.50 | x |
| 2023-12-31 | NT$28.82 | NT$51.50 | x |
| 2024-12-31 | NT$36.25 | NT$51.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently tsh biopharmoration Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.13%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.14%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 1.32x
- Recent ROE (8.13%) is above the historical average (5.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 5.67% | 13.36% | 0.38x | 1.12x | NT$-49.69 Million |
| 2018 | 5.16% | 11.21% | 0.42x | 1.09x | NT$-54.30 Million |
| 2019 | 7.58% | 16.81% | 0.40x | 1.12x | NT$-27.17 Million |
| 2020 | 5.47% | 13.75% | 0.36x | 1.09x | NT$-51.06 Million |
| 2021 | 4.35% | 11.39% | 0.35x | 1.08x | NT$-61.25 Million |
| 2022 | 5.45% | 8.35% | 0.52x | 1.26x | NT$-51.70 Million |
| 2023 | 5.60% | 7.64% | 0.58x | 1.26x | NT$-48.77 Million |
| 2024 | 8.13% | 10.14% | 0.61x | 1.32x | NT$-26.09 Million |
Industry Comparison
This section compares tsh biopharmoration Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,528,453,600
- Average return on equity (ROE) among peers: 3.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| tsh biopharmoration Ltd (8432) | NT$1.58 Billion | 5.67% | 0.17x | $23.56 Million |
| Grape King Bio Ltd (1707) | $11.79 Billion | 12.28% | 0.30x | $413.97 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $160.24 Million |
| Maywufa Co Ltd (1731) | $2.11 Billion | 8.22% | 0.51x | $41.33 Million |
| Allied Biotech Corporation (1780) | $1.17 Billion | 8.33% | 0.78x | $47.92 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.38 Billion | 5.16% | 0.21x | $180.77 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $24.30 Million |
| Easywell Biomedicals Inc. (1799) | $696.90 Million | -39.00% | 0.68x | $62.14 Million |
| LIWANLI Innovation Co Ltd (3054) | $799.59 Million | 4.48% | 0.55x | $49.55 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $292.12 Million |
| TTY Biopharm Co Ltd (4105) | $6.11 Billion | 22.00% | 0.56x | $486.74 Million |